Solid Biosciences

$2.16 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Solid Biosciences

Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD. Its lead program, SGT-001, is an adeno-associated virus (AAV) microdystrophin gene therapy candidate, which focuses on enabling the systemic delivery of a shortened yet functional version of the dystrophin gene. The Company is examining small molecule and biologic candidates that may help manage the secondary disorders associated with DMD. It is developing Wearable support for patients with DMD. The hardware of its assistive devices is composed of three technologies: force generating actuators (or motors), electrically controlled clutches, and harness technology called Flex Grip.

Stock Analysis

last close $2.16
1-mo return -18.8%
3-mo return -28.7%
avg daily vol. 912.56T
52-week high 11.58
52-week low 2.12
market cap. $248M
forward pe -
annual div. -
roe -56.1%
ltg forecast -
dividend yield -
annual rev. $7M
inst own. 73.7%
baraka

Subscribe now for daily local and international financial news

Subscribe